News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Mohammad Jad Moussa: An honor to cross paths with Dr. Tannir
Mohammad Jad Moussa/X
Feb 18, 2025, 08:09

Mohammad Jad Moussa: An honor to cross paths with Dr. Tannir

Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:

“Dr. Tannir, it’s an honor to cross paths with you thanks to Matt Campbell. Your legacy in kidney cancer will endure. Our experience with nivo/ipi in vhRCC, building upon CheckMate 920 and SUNNIFORECAST. Co-supervised with mentor Omar Alhalabi.”

cancer Matt Campbell MD Anderson Cancer Center Mohammad Jad Moussa Omar Alhalabi OncoDaily Oncology
Special Coverage
Blog
Apr 19, 2025, 00:49
Heba ElNokoudy: Comprehensive patient counseling significantly reduces adverse drug events
Blog
Apr 19, 2025, 00:20
Heba ElNokoudy: Comprehensive patient counseling significantly reduces adverse drug events
Blog
Apr 18, 2025, 20:22
Applications are open for the ESMO Research Fellowship
Blog
Apr 18, 2025, 20:12
Caitríona Duggan: Delighted for the opportunity to share our work at MASCC
Blog
Apr 18, 2025, 20:03
Fumiko Ladd Chino: Honored to be invited to speak about financial toxicity
Blog
Apr 18, 2025, 20:02
Estelamari Rodriguez: ACS NLCRT Biomarker Workshop version of brainstorming with the stars
Blog
Apr 18, 2025, 19:54
Sami Mansfield: Fiber, the microbiome, and cancer care
Blog
Apr 18, 2025, 19:49
Eric K. Singhi Discusses Lung Cancer at ASCO 2025
Science
Apr 18, 2025, 19:44
Nirmala Bhoo Pathy: The need for race and ethnicity data in cancer control
Science
Apr 18, 2025, 19:28
Andreas Charalambous: Achieving digital transformation in cancer care across Europe
Blog
Apr 18, 2025, 19:26
SIOG - Older adults deserve better: Let’s close the gap in Cancer Care
Science
Apr 18, 2025, 19:10
Rafael Grochot: The safety and activity of FGFR inhibitors in early-phase clinical trials